Favipiravir in High-risk COVID-19 Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

July 1, 2021

Study Completion Date

July 13, 2021

Conditions
Covid19
Interventions
DRUG

Favipiravir

Day 1: 1800mg BD, day 2-5: 800mg BD

Trial Locations (1)

10450

Penang General Hospital, George Town

All Listed Sponsors
collaborator

Enche' Besar Hajjah Khalsom Hospital

UNKNOWN

collaborator

Jasin Hospital

UNKNOWN

collaborator

Kepala Batas Hospital

OTHER_GOV

collaborator

Melaka Hospital

UNKNOWN

collaborator

Permai Hospital

UNKNOWN

collaborator

The Queen Elizabeth Hospital

OTHER

collaborator

Raja Perempuan Zainab II Hospital

UNKNOWN

collaborator

Raja Permaisuri Bainun Hospital

UNKNOWN

collaborator

Sultanah Aminah Hospital

UNKNOWN

collaborator

Hospital Sultanah Nur Zahirah, Kuala Terengganu

OTHER_GOV

collaborator

Sungai Buloh Hospital

UNKNOWN

collaborator

Tampin Hospital

UNKNOWN

collaborator

Tengku Ampuan Afzan Hospital

UNKNOWN

collaborator

Tuanku Fauziah Hospital

UNKNOWN

collaborator

Tuanku Jaafar Hospital

UNKNOWN

collaborator

Tumpat Hospital

UNKNOWN

collaborator

Institute for Clinical Research

OTHER

collaborator

Tawau Hospital

UNKNOWN

collaborator

Hulu Terrengganu Hospital

UNKNOWN

lead

Penang Hospital, Malaysia

OTHER_GOV